Oral Bisphosphonate-Related Osteonecrosis of the Jaw: Incidence, Clinical Features, Prevention, and Treatment Recommendations

Original Paper

DOI: 10.1007/s12018-009-9055-5

Cite this article as:
Yarom, N., Lazarovici, T.S. & Elad, S. Clinic Rev Bone Miner Metab (2010) 8: 27. doi:10.1007/s12018-009-9055-5

Abstract

Biphosphonate-related osteonecrosis of the jaw (BRONJ) is a devastating side effect of oral bisphosphonates associated with patient morbidity and high financial burden to health services. BRONJ is usually associated with parenteral use of bisphosphonates in oncologic patients, but its incidence among individuals with osteoporosis who take oral bisphosphonates is on the rise. In the absence of definitive treatment for BRONJ, every effort should be made toward its prevention. The patients must be informed about the extremely small but proven risk of oral BRONJ and be recommended to undergo periodic dental evaluation and meticulous oral hygiene. Once BRONJ occurs, long-term antibiotic therapy and superficial curettage may be beneficial.

Keywords

Alendronate Bisphosphonates Jaws Osteonecrosis Osteoporosis 

Copyright information

© Humana Press Inc. 2009

Authors and Affiliations

  • Noam Yarom
    • 1
    • 2
  • Towy Sorel Lazarovici
    • 3
  • Sharon Elad
    • 4
  1. 1.Oral Medicine Clinic, Department of Oral and Maxillofacial SurgerySheba Medical CenterTel-HashomerIsrael
  2. 2.Department of Oral Pathology and Oral Medicine, The Maurice and Gabriela Goldschleger School of Dental MedicineTel Aviv UniversityTel AvivIsrael
  3. 3.Department of Oral and Maxillofacial SurgerySheba Medical CenterTel-HashomerIsrael
  4. 4.Hospital Oral Medicine Service, Department of Oral Medicine, Hadassah School of Dental MedicineHebrew UniversityJerusalemIsrael

Personalised recommendations